A dietary pattern including nopal, chia seed, soy protein, and oat reduces serum triglycerides and glucose intolerance in patients with metabolic syndrome

Journal of Nutrition

Volumn 142, Issue 1, 2012, Pages 64-69

  Guevara Cruz, Martha ^a   Tovar, Armando R ^a   Aguilar Salinas, Carlos ^b   Medina Vera, Isabel ^a   Gil Zenteno, Lidia ^a   Hernández Viveros, Isaac ^a   López Romero, Patricia ^a   Ordaz Nava, Guillermo ^a   Canizales Quinteros, Samuel ^c,d   Pineda, Luz E Guillen ^b   Torres, Nimbe ^a  

^a Departamento de Fisiología de la Nutrición   (Mexico)

^b Departamento de Endocrinología y Metabolismo   (Mexico)

^c Instituto Nacional de Ciencias Médicas y Nu   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NOPAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOYBEAN PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CHIA SEED; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DIET THERAPY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; MEXICO; NUTRITIONAL ASSESSMENT; OAT; PARALLEL DESIGN; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PLANT SEED; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AREA UNDER CURVE; AVENA SATIVA; BLOOD GLUCOSE; DIET; DOUBLE-BLIND METHOD; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; METABOLIC SYNDROME X; MIDDLE AGED; PLACEBOS; SEEDS; SOYBEAN PROTEINS; TRIGLYCERIDES;

OPUNTIA;

EID: 84855543486     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.147447     Document Type: Article

References (51)

1. Aguilar-Salinas CA, J. Gómez-Pérez FJ, Valles V, R?́os-Torres JM, Franco A. Analysis of the agreement between the World Health Organization criteria and the national cholesterol education program III: definition of the metabolic syndrome: results from a population based survey. Diabetes Care. 2003;26:1635.
2. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J. High prevalence of metabolic syndrome in Mexico. Arch Med Res. 2004;35:76-81.
3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351-75.
4. Jenkins DJ, Josse AR, Wong JM, Nguyen TH, Kendall CW. The portfolio diet for cardiovascular risk reduction. Curr Atheroscler Rep. 2007;9:501-7.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
6. Grundy SM. The issue of statin safety: where do we stand? Circulation. 2005;111:3016-9.
7. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182-6.
8. Frati-Munari AC, Gordillo BE, Altamirano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care. 1988;11:63-6.
9. Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care. 2007;30:2804-10.
10. Lopez LO, G. Tovar, AR. Torres, N. Secretion of intestinal hormones is regulated by the consumption of nopal. FASEB J. 2008;22:701.6.
11. Ascencio C, Torres N, Isoard-Acosta F, Gomez-Perez FJ, Hernandez-Pando R, Tovar AR. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr. 2004;134:522-9.
12. Tovar AR, Torre-Villalvazo I, Ochoa M, Elias AL, Ortiz V, Aguilar- Salinas CA, Torres N. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res. 2005;46:1823-32.
13. Wood PJ, Braaten JT, Scott FW, Riedel KD, Wolynetz MS, Collins MW. Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load. Br J Nutr. 1994;72:731-43.
14. Maki KC, Beiseigel JM, Jonnalagadda SS, Gugger CK, Reeves MS, Farmer MV, Kaden VN, Rains TM. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J Am Diet Assoc. 2010;110:205-14.
15. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-98.
16. Ulbricht C, Chao W, Nummy K, Rusie E, Tanguay-Colucci S, Iannuzzi CM, Plammoottil JB, Varghese M, Weissner W. Chia (Salvia hispanica): a systematic review by the natural standard research collaboration. Rev Recent Clin Trials. 2009;4:168-74.
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
18. Canizales-Quinteros S, Aguilar-Salinas CA, Ortiz-Lopez MG, Rodriguez- Cruz M, Villarreal-Molina MT, Coral-Vazquez R, Huertas-Vazquez A, Hernandez-Caballero A, Lopez-Alarcon M, Brito-Zurita OR, et al. Association of PPARG2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Hum Biol. 2007; 79:111-9.
19. Cruz M, Valladares-Salgado A, Garcia-Mena J, Ross K, Edwards M, Angeles-Martinez J, Ortega-Camarillo C, de la Pena JE, Burguete- Garcia AI, Wacher-Rodarte N, et al. Candidate gene association study conditioning on individual ancestry in patients with type 2 diabetes and metabolic syndrome from Mexico City. Diabetes Metab Res Rev. 2010;26:261-70.
20. Burguete-Garcia AI, Cruz-Lopez M, Madrid-Marina V, Lopez-Ridaura R, Hernandez-Avila M, Cortina B, Gomez RE, Velasco-Mondragon E. Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study. Metabolism. 2010;59:38-45.
21. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodriguez-Cruz M, Miliar-Garcia A, Huertas- Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, et al. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes. 2008;57:509-13.
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
23. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13:322-7.
24. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:S51-209.
25. Perez-Lizaur AB, Gonzalez-Palacios B, Castro-Becerra A. L. Sistema Mexicano de Alimentos Equivalentes. 3rd ed. México, D.F.: Formatos de Nutricion y Salud; 2008.
26. Lohman TGM, Roche AF, Martorell R. Anthropometric standardization reference manual. Champagne (IL): Human Kinetics, 1998.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
28. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708-23.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
30. Tsai MY, Ordovas JM, Li N, Straka RJ, Hanson NQ, Arends VL, Arnett D. Effect of fenofibrate therapy and ABCA1 polymorphisms on highdensity lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab. 2010;100:118-22.
31. Emigh TH. A comparison of tests for Hardy-Weinberg equilibrium. Biometrics. 1980;36:627-42.
32. Wolever TM, Jenkins DJ, Jenkins AL, Josse R. The glycemic index: methodology and clinical implications. Am J Clin Nutr. 1991;54:846-54.
33. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-36.
34. Rojas R, Aguilar-Salinas CA, Jimenez-Corona A, Shamah-Levy T, Rauda J, Avila-Burgos L, Villalpando S, Ponce EL. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S11-8.
35. Schiltz B, Minich DM, Lerman RH, Lamb JJ, Tripp ML, Bland JS. A science-based, clinically tested dietary approach for the metabolic syndrome. Metab Syndr Relat Disord. 2009;7:187-92.
36. Vuksan V, Jenkins AL, Dias AG, Lee AS, Jovanovski E, Rogovik AL, Hanna A. Reduction in postprandial glucose excursion and prolongation of satiety: possible explanation of the long-term effects of whole grain Salba (Salvia Hispanica L.). Eur J Clin Nutr. 2010;64:436-8.
37. Torres N, Guevara-Cruz M, Granados J, Vargas-Alarcon G, Gonzalez- Palacios B, Ramos-Barragan VE, Quiroz-Olguin G, Flores-Islas IM, Tovar AR. Reduction of serum lipids by soy protein and soluble fiber is not associated with the ABCG5/G8, apolipoprotein E, and apolipoprotein A1 polymorphisms in a group of hyperlipidemic Mexican subjects. Nutr Res. 2009;29:728-35.
38. Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Van Horn L, Liu K, Turnbull WH, Thye FW, Kestin M, et al. Oat products and lipid lowering. A meta-analysis. JAMA. 1992;267:3317-25.
39. Chicco AG, D'Alessandro ME, Hein GJ, Oliva ME, Lombardo YB. Dietary chia seed (Salvia hispanica L.) rich in alpha-linolenic acid improves adiposity and normalises hypertriacylglycerolaemia and insulin resistance in dyslipaemic rats. Br J Nutr. 2009;101:41-50.
40. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42.
41. Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev. 2009;67:188-205.
42. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond). 2009;116:1-16.
43. Noriega-López L, Tovar AR, Gonzalez-Granillo M, Hernandez-Pando R, Escalante B, Santillan-Doherty P, Torres N. Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem. 2007;282:20657-66.
44. Phillips CM, Tierney AC, Roche HM. Gene-nutrient interactions in the metabolic syndrome. J Nutrigenet Nutrigenomics. 2008;1:136-51.
45. Acuña-Alonzo V, Flores-Dorantes T, Kruit JK, Villarreal-Molina T, Arellano-Campos O, Hunemeier T, Moreno-Estrada A, Ortiz-Lopez MG, Villamil-Ramirez H, Leon-Mimila P, et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet. 2010;19:2877-85.
46. Guevara-Cruz M, Tovar AR, Larrieta E, Canizales-Quinteros S, Torres N. Increase in HDL-C concentration by a dietary portfolio with soy protein and soluble fiber is associated with the presence of the ABCA1R230C variant in hyperlipidemic Mexican subjects. Mol Genet Metab. 2010;101:268-72.
47. Esposito K, Ceriello A, Giugliano D. Diet and the metabolic syndrome. Metab Syndr Relat Disord. 2007;5:291-6.
48. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-7.
49. Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Brunham LR, Verchere CB, Hayden MR. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia. 2010;53:1110-9.
50. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328-38.
51. Ordovas JM. Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc. 2006;106:1074-81.